> Andrew Xu
Andrew is a life science executive with more than 25 years of experience in strategy and organization, Merger & Acquisition, capital deployment in global pharmaceutical business.
He served as President and Vice Chairman of Porton Fine Chemicals ("Porton") for 10 years when Andrew led equity restructuring and oversaw the company's initial public offering in 2014 (SZ300363). He also led multiple international Mergers & Acquisitions to expand Porton’ business to global markets.
Prior to Porton, Andrew served several executive positions with increasing responsibility such as Executive Vice President in Shanghai Eastbound Technology, Vice President of Shanghai Zillion High Tech, Director of R&D and Quality in Yunshin Pharmaceutical.
Andrew is a recipient of Excellent Professional and Technical Talents from Changning, Shanghai and multiple awards on products innovation, also an inventor of multiple domestic and international patents.
He received his bachelor degree from East China University of Science and Technology, earned his PhD of Medicinal Chemistry from Shanghai Institute of Pharmaceutical Industry, and studied AMP course of CEIBS and CEO course of Cheung Kong Business School.